Table 1 Clinical and laboratory features of JIA patients enrolled in the study
Patient | JIA form | Disease duration (years) | Number of active joints | CRP (mg/dl) | ANA | Treatment |
|---|---|---|---|---|---|---|
1 | Oligo pers | 8 | 1 | 1.32 | Pos | NSAID |
2 | Oligo pers | 6 | 1 | <0.46 | Pos | --- |
3 | Oligo pers | 2 | 2 | 0.83 | Pos | --- |
4 | Oligo pers | 6 | 3 | 0.76 | Pos | NSAID |
5 | Oligo pers | 8 | 2 | 1.85 | Pos | NSAID |
6 | Oligo pers | 1 | 2 | <0.46 | Pos | NSAID |
7 | Oligo pers | 5 | 1 | <0.46 | Pos | --- |
8 | Oligo pers | 10 | 1 | <0.46 | Neg | --- |
9 | Oligo pers | 6 | 1 | 0.61 | Pos | --- |
10 | Oligo pers | 1 | 1 | <0.46 | Pos | --- |
11 | Oligo pers | 5 | 1 | <0.46 | Pos | --- |
12 | Oligo pers | 1 | 1 | <0.46 | Pos | NSAID |
13 | Oligo pers | 9 | 1 | <0.46 | Pos | NSAID |
14 | Oligo ext | 6 | 2 | 8.3 | Pos | NSAID, MTX |
15 | Oligo ext | 6 | 6 | 6.59 | Pos | NSAID |
16 | Oligo ext | 3 | 4 | 3.5 | Pos | NSAID, MTX |
17 | Oligo ext | 11 | 1 | <0.46 | Pos | MTX |
18 | Oligo ext | 10 | 8 | 1.25 | Pos | NSAID |
19 | Oligo ext | 10 | 4 | 2.53 | Pos | CyA, MTX |
20 | Oligo ext | 1 | 4 | 0.87 | Pos | NSAID |
21 | Oligo ext | 2 | 5 | 1.34 | Pos | NSAID |
22 | Oligo ext | 10 | 1 | 0.6 | Pos | MTX |
23 | Oligo ext | 2 | 1 | <0.46 | Pos | NSAID, MTX |
24 | Poly RF | 5 | 2 | 0.87 | Pos | MTX |
25 | Poly RF | 9 | 1 | 0.76 | Neg | NSAID, adalimumab |